Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Interest & Investment Income: 2009-2013

Historic Interest & Investment Income for Northwest Biotherapeutics (NWBO) over the last 1 years, with Dec 2013 value amounting to $1.7 million.

  • Northwest Biotherapeutics' Interest & Investment Income changed negligibly% to $1.7 million in Q4 2013 from the same period last year, while for Dec 2013 it was $5.6 million, marking a year-over-year increase of 473.62%. This contributed to the annual value of $489,000 for FY2010, which is 59.85% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Interest & Investment Income stood at $1.7 million for Q4 2013, which was down 0.00% from $1.7 million recorded in Q2 2013.
  • Northwest Biotherapeutics' Interest & Investment Income's 5-year high stood at $1.7 million during Q4 2012, with a 5-year trough of -$2.4 million in Q4 2009.
  • Over the past 2 years, Northwest Biotherapeutics' median Interest & Investment Income value was $1.7 million (recorded in 2013), while the average stood at $1.7 million.
  • Data for Northwest Biotherapeutics' Interest & Investment Income shows a peak YoY spiked of 120.07% (in 2010) over the last 5 years.
  • Quarterly analysis of 4 years shows Northwest Biotherapeutics' Interest & Investment Income stood at -$2.4 million in 2009, then surged by 120.07% to $489,000 in 2010, then reached $1.7 million in 2012, then remained steady at $1.7 million in 2013.
  • Its Interest & Investment Income was $1.7 million in Q4 2013, compared to $1.7 million in Q2 2013 and $1.7 million in Q4 2012.